Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Afatinib to gain ground in non-small cell lung cancer markets outside the US

bs_subtitle

Promising recent clinical trial data for the tyrosine kinase inhibitor (TKI) afatinib (Gilotrif) will strengthen the drug’s position in non-small cell lung cancer (NSCLC) treatment markets outside the US, says an analyst with research and consulting firm GlobalData. The LUX-Lung 7 trial showed afatinib to reduce the risk of adenocarcinoma progression for patients with epidermal growth factor receptor (EGFR) mutations by 27% compared with one of its closest rivals, AstraZeneca’s gefitinib (Iressa). The differential in progression-free survival at 18 months was 27% for afatinib and 15% for gefitinib, increasing further at 24 months, to 18% and 8%, respectively. According to Cai Xuan, GlobalData’s analyst covering Oncology and Hematology, these recent

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy